MX2013000821A - Nuevas aminopirazoloquinazolinas. - Google Patents
Nuevas aminopirazoloquinazolinas.Info
- Publication number
- MX2013000821A MX2013000821A MX2013000821A MX2013000821A MX2013000821A MX 2013000821 A MX2013000821 A MX 2013000821A MX 2013000821 A MX2013000821 A MX 2013000821A MX 2013000821 A MX2013000821 A MX 2013000821A MX 2013000821 A MX2013000821 A MX 2013000821A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- aminopyrazoloquinazolines
- new
- compounds
- medicaments
- Prior art date
Links
- SUOYKOLHSZCPPT-UHFFFAOYSA-N C1=CC2=NN=CC2=C2NC(N)=NC=C21 Chemical class C1=CC2=NN=CC2=C2NC(N)=NC=C21 SUOYKOLHSZCPPT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10170683 | 2010-07-23 | ||
| PCT/EP2011/062683 WO2012010704A1 (en) | 2010-07-23 | 2011-07-22 | New aminopyrazoloquinazolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013000821A true MX2013000821A (es) | 2013-05-30 |
Family
ID=43037625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013000821A MX2013000821A (es) | 2010-07-23 | 2011-07-22 | Nuevas aminopirazoloquinazolinas. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8735386B2 (enExample) |
| EP (1) | EP2595987B1 (enExample) |
| JP (1) | JP5991974B2 (enExample) |
| KR (1) | KR20130132394A (enExample) |
| CN (1) | CN103097388A (enExample) |
| AP (1) | AP2012006640A0 (enExample) |
| AR (1) | AR082850A1 (enExample) |
| AU (1) | AU2011281504A1 (enExample) |
| BR (1) | BR112013000107A2 (enExample) |
| CA (1) | CA2803467A1 (enExample) |
| CL (1) | CL2012003745A1 (enExample) |
| CO (1) | CO6670575A2 (enExample) |
| EA (1) | EA201201661A1 (enExample) |
| EC (1) | ECSP13012448A (enExample) |
| GE (1) | GEP20156289B (enExample) |
| MA (1) | MA34389B1 (enExample) |
| MX (1) | MX2013000821A (enExample) |
| PE (1) | PE20131143A1 (enExample) |
| PH (1) | PH12013500152A1 (enExample) |
| SG (1) | SG187548A1 (enExample) |
| TW (1) | TW201217380A (enExample) |
| UY (1) | UY33526A (enExample) |
| WO (1) | WO2012010704A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2807166B1 (en) | 2012-01-23 | 2016-04-06 | Boehringer Ingelheim International GmbH | 5,8-dihydro-6h-pyrazolo[3,4-h]quinazolines as igf-1r/ir inhibitors |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| SMT201900291T1 (it) * | 2013-11-15 | 2019-07-11 | Oncoceutics Inc | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso |
| SMT202500087T1 (it) | 2015-01-30 | 2025-03-12 | Oncoceutics Inc | Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia |
| WO2016180843A1 (en) * | 2015-05-13 | 2016-11-17 | Boehringer Ingelheim International Gmbh | New 5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h]quinazolin-2- yl)-(1 h-pyrazol-3-yl)-amines and derivatives as igf-1 r/ir inhibitors |
| CN108699067B (zh) * | 2016-11-11 | 2021-06-15 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 |
| KR102420892B1 (ko) * | 2017-05-26 | 2022-07-14 | 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 | 요산 배출을 촉진시키는 urat1 억제제 |
| CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
| EP3786161A4 (en) * | 2018-04-24 | 2021-05-05 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd | CDK4 / 6 INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC THEREOF, AND USE OF IT |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US12311048B2 (en) | 2018-11-02 | 2025-05-27 | Fount Bio, Inc. | Crosslinked materials |
| EP3917514A4 (en) * | 2019-01-30 | 2023-02-22 | Yale University | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF FIBROSIS |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| CU24679B1 (es) * | 2019-03-07 | 2023-09-07 | BioNTech SE | Proceso para la preparación de una imidazoquinolina sustituida |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020214889A1 (en) * | 2019-04-19 | 2020-10-22 | Fount Bio, Inc. | Delivery and retention of active agents within the skin |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| CN116057045B (zh) | 2020-06-05 | 2026-06-09 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶抑制剂 |
| CN111960974A (zh) * | 2020-08-28 | 2020-11-20 | 山东潍坊润丰化工股份有限公司 | 一种烯草酮中间体的合成方法 |
| US12577253B2 (en) | 2021-02-08 | 2026-03-17 | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. | 5,6-dihydrothieno[3,4-h]quinazoline compound |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9610823A (pt) * | 1995-10-02 | 1999-07-13 | Hoffmann La Roche | Derivados de pirimidina como antagonistas do receptor |
| ES2436524T3 (es) | 2003-05-22 | 2014-01-02 | Nerviano Medical Sciences S.R.L. | Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
-
2011
- 2011-07-20 US US13/187,100 patent/US8735386B2/en active Active
- 2011-07-21 UY UY0001033526A patent/UY33526A/es not_active Application Discontinuation
- 2011-07-22 CA CA2803467A patent/CA2803467A1/en not_active Abandoned
- 2011-07-22 BR BR112013000107A patent/BR112013000107A2/pt not_active IP Right Cessation
- 2011-07-22 WO PCT/EP2011/062683 patent/WO2012010704A1/en not_active Ceased
- 2011-07-22 AU AU2011281504A patent/AU2011281504A1/en not_active Abandoned
- 2011-07-22 EA EA201201661A patent/EA201201661A1/ru unknown
- 2011-07-22 EP EP11734158.6A patent/EP2595987B1/en active Active
- 2011-07-22 GE GEAP201113008A patent/GEP20156289B/en unknown
- 2011-07-22 AR ARP110102670A patent/AR082850A1/es unknown
- 2011-07-22 JP JP2013520164A patent/JP5991974B2/ja active Active
- 2011-07-22 SG SG2013003645A patent/SG187548A1/en unknown
- 2011-07-22 KR KR1020137003430A patent/KR20130132394A/ko not_active Withdrawn
- 2011-07-22 TW TW100126062A patent/TW201217380A/zh unknown
- 2011-07-22 PE PE2013000125A patent/PE20131143A1/es not_active Application Discontinuation
- 2011-07-22 MA MA35577A patent/MA34389B1/fr unknown
- 2011-07-22 CN CN201180043930XA patent/CN103097388A/zh active Pending
- 2011-07-22 AP AP2012006640A patent/AP2012006640A0/xx unknown
- 2011-07-22 MX MX2013000821A patent/MX2013000821A/es active IP Right Grant
- 2011-07-22 PH PH1/2013/500152A patent/PH12013500152A1/en unknown
-
2012
- 2012-12-28 CL CL2012003745A patent/CL2012003745A1/es unknown
-
2013
- 2013-01-22 CO CO13011464A patent/CO6670575A2/es active IP Right Grant
- 2013-02-19 EC ECSP13012448 patent/ECSP13012448A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20156289B (en) | 2015-05-25 |
| AU2011281504A1 (en) | 2013-01-10 |
| AR082850A1 (es) | 2013-01-16 |
| EA201201661A1 (ru) | 2013-07-30 |
| EP2595987B1 (en) | 2018-04-18 |
| AP2012006640A0 (en) | 2012-12-31 |
| JP5991974B2 (ja) | 2016-09-14 |
| BR112013000107A2 (pt) | 2016-05-17 |
| PH12013500152A1 (en) | 2013-02-18 |
| US8735386B2 (en) | 2014-05-27 |
| CN103097388A (zh) | 2013-05-08 |
| CA2803467A1 (en) | 2012-01-26 |
| UY33526A (es) | 2012-02-29 |
| JP2013532652A (ja) | 2013-08-19 |
| SG187548A1 (en) | 2013-03-28 |
| US20120238542A1 (en) | 2012-09-20 |
| WO2012010704A1 (en) | 2012-01-26 |
| KR20130132394A (ko) | 2013-12-04 |
| CO6670575A2 (es) | 2013-05-15 |
| PE20131143A1 (es) | 2013-10-23 |
| MA34389B1 (fr) | 2013-07-03 |
| EP2595987A1 (en) | 2013-05-29 |
| CL2012003745A1 (es) | 2013-05-31 |
| ECSP13012448A (es) | 2013-03-28 |
| TW201217380A (en) | 2012-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500152A1 (en) | New aminopyrazoloquinazolines | |
| PH12015501074A1 (en) | Triazolopyrazine | |
| TN2012000369A1 (en) | 5-alkynyl-pyrimidines | |
| MX2009013935A (es) | Compuestos quimicos. | |
| PH12013501618A1 (en) | New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | |
| MX2011012643A (es) | 2,4-diaminopiridinas para el tratamiento de enfermedades caracterizadas por la proliferacion celular excesiva o anormal. | |
| MY176944A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| PH12015501385A1 (en) | Autotaxin inhibitors | |
| MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
| PH12014502524A1 (en) | Carboxylic acid compounds | |
| WO2010007116A3 (en) | Pyridons as pdk1 inhibitors | |
| PH12014501913A1 (en) | New 5-alkynyl pyridine | |
| MX2014007897A (es) | Nuevos derivados de azetidina, composiciones farmaceuticas y sus usos. | |
| PH12013500007A1 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| TN2011000531A1 (en) | 5- alkynyl - pyridines | |
| MX2010009837A (es) | Tiazolil-dihidro-indazoles. | |
| IN2012DN06600A (enExample) | ||
| TN2013000012A1 (en) | New aminopyrazoloquinazolines | |
| WO2012022796A3 (de) | Neue kombinationen | |
| TN2011000610A1 (en) | 2,4-diaminopyrimidines for the treatment of diseases characterised b y excessive or abnormal cell proliferation | |
| TN2011000049A1 (en) | 5-alkynyl-pyrimidines | |
| TN2010000408A1 (en) | Thiazolyl-dihydro-indazoles | |
| UA107920C2 (en) | Substituted pyrimidine for the treatment of diseases such as cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |